BAXTER INTL INC shareholders Q3 2020

BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,088 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.

BAXTER INTL INC shareholders Q3 2020
NameSharesValueWeighting ↓
SENTRY INVESTMENT MANAGEMENT LLC 31,697$2,549,0000.14%
IFM Investors Pty Ltd 41,792$3,361,0000.14%
Drexel Morgan & Co. 4,997$402,0000.14%
BOKF, NA 79,653$6,405,0000.14%
Gulf International Bank (UK) Ltd 122,732$9,870,0000.14%
DOWLING & YAHNKE LLC 21,594$1,737,0000.14%
VICTORY CAPITAL MANAGEMENT INC 1,346,190$108,261,0000.14%
EVERENCE CAPITAL MANAGEMENT INC 15,757$1,267,0000.14%
MITCHELL MCLEOD PUGH & WILLIAMS INC 3,346$269,0000.14%
Legal & General Group Plc 3,822,804$307,429,0000.14%
National Pension Service 657,758$52,318,0000.14%
Pekin Hardy Strauss, Inc. 8,267$665,0000.14%
London & Capital Asset Management Ltd 12,510$1,006,0000.14%
PRIO WEALTH LIMITED PARTNERSHIP 40,424$3,251,0000.14%
Linscomb Wealth, Inc. 24,105$1,939,0000.13%
Treasurer of the State of North Carolina 221,420$17,807,0000.13%
GABELLI FUNDS LLC 213,950$17,206,0000.13%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 693,507$55,771,0000.13%
Codex Capital, L.L.C. 2,500$205,0000.13%
BlackRock Inc. 44,599,949$3,586,729,0000.13%
About BAXTER INTL INC

Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.

Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.

Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.

Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.

Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BAXTER INTL INC's shareholders in Q3 2020. To view BAXTER INTL INC's shareholder history, click here.